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INTRODUCTION
In clinical practice, using pharmacogenetics has risen in
importance since the technologies for genomic variation
searches for different responses to drugs became wide-
spread, easier, more rapid, and affordable for a specialized
laboratory. The main pharmacogenetics studies have mostly
involved drug resistance monitoring in oncology patients;1
however, other applications are being developed to detect
genetic molecular markers associated with resistance or
hypersensitivity/adverse reactions to antiretroviral drug
treatment in Human Immunodeficiency Virus (HIV)-
infected patients.2
HIV treatment is known to be limited by adverse drug
reactions and the development of resistance. One signifi-
cant example is the strong association of the Abacavir
hypersensitivity reaction with HLA-B*5701 in HIV-positive
patients.3 Abacavir, a common drug for treating HIV-
infected patients, is an efficient nucleoside reverse-tran-
scriptase inhibitor with a beneficial long-term toxicity
profile, often used with other antiretroviral agents.
However, Abacavir can yield adverse effects such as
immunologically-driven hypersensitivity in 5 to 8% of
HIV-positive subjects during the first six weeks of use.2
Hypersensitivity symptoms immediately reverse after the
interruption of Abacavir.4
The hypersensitivity reaction to Abacavir has been
reportedly associated with the presence of the major
histocompatibility complex class I allele HLA-B*5701 and
this association has been confirmed in several replication
studies in different ethnic groups of HIV-positive patients.3
In our study, we searched for the presence of HLA B*5701
in 96 HIV-positive patients treated with Abacavir and in
243 healthy subjects from Northeastern Brazil (Recife,
Pernambuco) to verify the percentage of HLA B*5701 allele
carriers in HIV patients and in the general population from
Northeast Brazil. This area is known to harbor a tri-hybrid
population resulting from contributing African (44%),
Caucasian (34%), and native American (22%) genomes.5
MATERIAL AND METHODS
Subjects
Genomic DNA of 96 HIV-infected patients (50 males,
mean age 29.5 years, range 19-48; 46 females, mean age 22.7,
range 16-31) treated with Abacavir and 243 healthy blood
donors (120 males, mean age 21.3 years, range 18-41; 123
females, mean age 24.2 years, range 19-48) from the Recife
metropolitan area stored at the ‘‘Laborato´rio Central de
Sau´de Pu´blica - Dr. Milton Bezerra Sobral’’ (LACEN - PE)
and the ‘‘Laboratorio de Imunopatologia Keizo Azami’’
(LIKA) were used for the genetic screening. Genomic DNA
was previously extracted from peripheral whole blood and
stored at 220 C˚ at the LIKA laboratory of Recife using the
EZ1 DNA extraction kit and EZ1 robotic device (Quiagen)
following the manufacturer’s instructions.
Patients and controls were stratified for ethnicity and
classified as European- or African-derived according to
phenotypic characteristics of individuals and ethnicity data
of parents/grandparents reported by the participants in an
appropriate questionnaire. The issue concerning the skin
color-based classification criteria adopted in Brazil is well-
documented and has been already assessed by other
research groups in previous studies.6,7
HLA B*5701 genotyping
HLA B*5701 genotyping has been performed in triplicate
by Melting Temperature Assay using the DUPLICa-
RealTime HLA-B*5701 Genotyping kit (Euroclone, Milan,
Italy). Briefly, 5 ml of genomic DNA (50 ng/ml) were added
to 10 ml of amplification mix (with Hot Start Taq DNA
polymerase, nucleotides, MgCl2, buffer and SYBR GREEN)
and 10 ml of oligo mix (with primers to amplify HLA-B*5701
allele and an internal control, human growth hormone:
HGH). Real time PCR reactions were run on the Cepheid
(Euroclone, Milan, Italy) platform using the following
temperatures and cycles profile: 29 50 C˚ 1 hold, 109 95 C˚ 1
hold, then 40 cycles 150 95 C˚ and 600 60 C˚. The melting
protocol was as follows: initial hold 29 65 C˚ with a melting
curve from 65 C˚ to 95 C˚ increasing 0.2 C˚ each time. Each
specific amplicon (i.e. HLA B*5701 and HGM) was
detectable by a different melting temperature.
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RESULTS
We searched for the presence of HLAB*5701 allele in 96
HIV-infected patients treated with Abacavir and 243
Northeastern Brazilian subjects from Recife (PE) using a real
time allelic-specific PCR approach. The melting temperature
assay, performed after real time PCR amplification, allowed
us to easily identify the presence of HLA B*5701, character-
ized by a melting profile temperature between 91.5 and
92.5 C˚, while the internal control, the human beta globin
gene, showed a melting temperature between 88.8 and
89.8 C˚. Figure 1 shows the melting profiles of the
HLAB*5701 positive and HLAB*5701 negative samples.
The real time PCR followed by melting temperature assay
were performed in triplicate on three different real time PCR
platforms to test the robustness of the genotyping chemistry
and its adaptability to different technological platforms. The
results obtained by using the ABI 7900 HT Sequence Detection
System, the RotorGene 3000 and the Cepheid (Euroclone,
Milan Italy) real time PCR platforms were absolutely the same
and were highly reproducible, always allowing the detection
of the HLA B*5701 allele in the unknown genotype samples.
Within the 96 HIV infected patients treated with
Abacavir, three (3.1%) were carriers of the HLA B*5701
allele and presented with hypersensitivity characterized by
cutaneous rash and severe gastrointestinal tract symptoms;
in the control population, eight individuals out of the 243
screened (3.4%) were carriers for HLA B*5701. The HLA
B*5701 allele was heterozygous in all carriers (the results
were double-checked using the PCR-SSP Dynal commercial
kit). Table 1 summarizes the results for the HIV patients and
the controls from Northeast Brazil and reports HLA B*5701
carriers and allele frequencies for other ethnic groups
(reported in the http://www.allelefrequencies.net).8
When stratifying for ethnicity, within the 96 HIV infected
patients 36 were European-derived (two HLA B*5701
carriers, 5.5%) and 60 were African-derived (one HLA
B*5701 carrier, 1.6%). In the controls group, 90 individuals
were classified as European-derived (five HLA B*5701
carriers, 5.5%) and 153 were classified as African-derived
(three HLA B*5701 carriers, 1.9%).
DISCUSSION
Recently, the presence of the HLA-B*5701 allele has been
correlated with immunological hypersensitivity to Abacavir
in white and black HIV-positive patients from United States.9
Moreover, HLA-B*5701 allele carriers in HIV-positive
Hispanic patients showed a clinically-diagnosed hypersensi-
tivity reaction to Abacavir.10 HLA-B*5701 allele frequency is
known to depend upon the HIV-positive patients’ ethnicity;
in fact, while white Caucasians have an incidence of around
Figure 1 - Melting temperature assay profiles of two subjects: one carrier of HLA B*5701 allele (A) and one non-carrier of the HLA
B*5701 allele (B). The two melting profiles are easily distinguishable and allow easy detection of the HLA B*5701 allele.
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6%, only about 2.5% present in the black population.11 Thus,
the screening for a genetic marker for hypersensitivity to
Abacavir, such as the HLA-B*5701, is strongly dependent
upon the population’s racial background.
In our study performed with Northeastern Brazilian
individuals, the frequency of HLA-B*5701 carriers was
3.1% in HIV-infected patients and 3.4% in the general
population. These frequencies are between those reported
for white Caucasian and black subjects from the United
States. The difference can be explained by the ethnic
composition of the Pernambuco population, known to be
an admixture of Caucasian (34%), Afro-American (44%),
and Amerindian (22%) genomes.5 Moreover, our findings
more closely resembled those by Poggi et al.12 in HIV
patients and the controls from Chile than the frequencies
reported in a Caucasian population from Belo Horizonte
(see Table 1 reporting HLA B*5701 frequencies in different
ethnic groups for comparison).8
The importance of HLA-B*5701 screening for diminishing
the frequency of hypersensitivity to Abacavir has been
reported in the PREDICT-1 study13; the frequency of HLA
B*5701 carriers at high risk of hypersensitivity to Abacavir
was 6% in white Caucasian patients.
In our study population from Northeastern Brazil, the
frequency of HLA-B*5701 was between Caucasian and
African ethnic groups; however, when stratifying for
ethnicity, our findings show that the HLA B*5701 carriers’
frequencies are more similar to those previously reported
for Caucasians and Africans.
Finally, considering the clinical importance of hypersen-
sitivity to Abacavir treatment in HIV-infected patients and
the frequency of HLA B*5701 carriers reported in this study
(3.1% in patients and 3.4% in the controls), we suggest the
preventive use of HLA B*5701 testing in clinical practice in
Abacavir treatment in Northeastern Brazil.
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Table 1 - HLA B*5701 frequencies in HIV-infected patients (HIV_BRA) and the controls (BRA_NE) from Northeast Brazil in
this study and in previously genotyped populations9 (http://www.allelefrequencies.net).
HIV_BRA
n=96
BRA_NE
n=234
BRA_C
n=95
HIV_CHI
n=492
CHI_P
n=300
CHI_M
n=70
AUT_C
n=200
USA_A
n=187
USA_C
n=307
H L A B * 5 7 0 1
carriers
3.1% 3.4% 1.1% 2.2% 3.7% 4.0% 5.5% 2.1% 6.2%
H L A B * 5 7 0 1
allele frequency
1.5% 1.7% 0.5% 1.1% 1.8% 2.0% 2.8% 1.1% 3.1%
BRA_C: Brazil (Belo Horizonte) Caucasian; HIV_CHI: HIV infected patients from Chile: CHI_P: Chilean general population; CHI_M: Chile (Santiago) Mixed;
AUT_C: Austria Caucasian; USA_A: USA (Bethesda) African-American; USA_C: USA (Philadelphia) Caucasian.
CLINICS 2011;66(8):1485-1487 HLA-B*5701 carriers in Northeast Brazil
Crovella S et al.
1487
